Compounds > chloroquine
Page last updated: 2024-10-24

chloroquine and Acquired Immunodeficiency Syndrome

chloroquine has been researched along with Acquired Immunodeficiency Syndrome in 12 studies

Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.

Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.

Research Excerpts

ExcerptRelevanceReference
"Chloroquine and related anti-malarial drugs appear to promote apoptosis in T-cells by suppressing NF-kappa-B, which enhances the expression of anti-apoptotic proteins (e."7.72Hypothesis links emergence of chloroquine-resistant malaria and other intracellular pathogens and suggests a new strategy for treatment of diseases caused by intracellular parasites. ( Parris, GE, 2004)
"The widespread emergence of chloroquine-resistant Plasmodium falciparum led to the formulation of an effective, fixed combination of two antimalarial agents, pyrimethamine and the long-acting sulfonamide sulfadoxine, for prophylaxis and treatment."4.77Use of pyrimethamine-sulfadoxine (Fansidar) in prophylaxis against chloroquine-resistant Plasmodium falciparum and Pneumocystis carinii. ( Hewlett, EL; Pearson, RD, 1987)
"Chloroquine and related anti-malarial drugs appear to promote apoptosis in T-cells by suppressing NF-kappa-B, which enhances the expression of anti-apoptotic proteins (e."3.72Hypothesis links emergence of chloroquine-resistant malaria and other intracellular pathogens and suggests a new strategy for treatment of diseases caused by intracellular parasites. ( Parris, GE, 2004)
"Five cases of malaria were detected among cocaine users by the local health service in Bauru, a city with a population of 260,000, located 324 km from S."3.68[Outbreak of malaria induced among users of injectable drugs]. ( Andriguetti, MT; Barata, LC; de Matos, MR, 1993)
"Chloroquine is a 9-aminoquinoline known since 1934."2.42Effects of chloroquine on viral infections: an old drug against today's diseases? ( Boelaert, JR; Cassone, A; Cauda, R; Majori, G; Savarino, A, 2003)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19903 (25.00)18.7374
1990's3 (25.00)18.2507
2000's3 (25.00)29.6817
2010's2 (16.67)24.3611
2020's1 (8.33)2.80

Authors

AuthorsStudies
Aminake, MN1
Mahajan, A1
Kumar, V1
Hans, R1
Wiesner, L1
Taylor, D1
de Kock, C1
Grobler, A1
Smith, PJ1
Kirschner, M1
Rethwilm, A1
Pradel, G1
Chibale, K1
Berlivet, L1
Löwy, I1
Dos-Santos, JC1
Angerami, RN1
Castiñeiras, CM1
Lopes, SC1
Albrecht, L1
Garcia, MT1
Levy, CE1
Moretti, ML1
Lacerda, MV1
Costa, FT1
Savarino, A1
Boelaert, JR1
Cassone, A1
Majori, G1
Cauda, R1
Parris, GE2
Barata, LC1
Andriguetti, MT1
de Matos, MR1
Campos, JM1
Simonetti, JP1
Bagla, P1
Shoemaker, JP1
Pearson, RD1
Hewlett, EL1
Kagan, BL1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19)[NCT04627467]Phase 23,217 participants (Actual)Interventional2020-03-28Completed
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation[NCT00819390]Phase 270 participants (Actual)Interventional2009-03-31Completed
Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416]Phase 3204 participants (Anticipated)Interventional2020-06-02Active, not recruiting
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA)[NCT04844099]Phase 3723 participants (Actual)Interventional2021-04-09Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 12

The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At pre-entry, entry, weeks 10 and 12

Interventionpercent of CD8 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants-2.0
B: Placebo Then Chloroquine for Off-ART Participants-0.5
C: Chloroquine Then Placebo for On-ART Participants-3.1
D: Placebo Then Chloroquine for On-ART Participants-1.2

Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 24 in Arm A and Arm C

The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Pre-entry, entry, Weeks 22 and 24

Interventionpercent of CD8 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants10.8
C: Chloroquine Then Placebo for On-ART Participants-2.4

Change in Percent CD8 HLA-DR+/CD38+ From Start to End of the 12-week Chloroquine Treatment Period

For Arm A: Chloroquine then Placebo for off-ART participants and Arm C: Chloroquine then Placebo for on-ART participants, the baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. For Arm B: Placebo then Chloroquine for off-ART participants and Arm D: Placebo then Chloroquine for on-ART participants, the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: For Arms A and C: Pre-entry, entry, weeks 10 and 12. For Arms B and D: Weeks 10, 12, 22 and 24

Interventionpercent of CD8 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants-2.0
B: Placebo Then Chloroquine for Off-ART Participants1.5
C: Chloroquine Then Placebo for On-ART Participants-3.1
D: Placebo Then Chloroquine for On-ART Participants-2.9

Change in Percent CD8 HLA-DR+/CD38+ From Week 12 to Week 24

The mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ is subtracted from the mean of the week 22 and week 24 percent CD8 HLA-DR+/CD38+ (NCT00819390)
Timeframe: At Weeks 10, 12, 22 and 24

Interventionpercent of CD8 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants5.5
B: Placebo Then Chloroquine for Off-ART Participants1.5
C: Chloroquine Then Placebo for On-ART Participants-0.1
D: Placebo Then Chloroquine for On-ART Participants-2.9

Change in Total CD4 T Cell Count From Baseline to Week 12

Baseline CD4 count (mean of pre-entry and entry CD4 count) is subtracted from the mean of week 10 and week 12 CD4 count (NCT00819390)
Timeframe: At pre-entry, entry, weeks 10 and 12

Interventioncells/mm^3 (Median)
A: Chloroquine Then Placebo for Off-ART Participants-27
B: Placebo Then Chloroquine for Off-ART Participants-11
C: Chloroquine Then Placebo for On-ART Participants-6
D: Placebo Then Chloroquine for On-ART Participants7

Fasting Lipopolysaccharides (LPS) at Entry

Results reported are for entry fasting LPS. (NCT00819390)
Timeframe: At entry

Interventionpg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants13.68
B: Placebo Then Chloroquine for Off-ART Participants1.64
C: Chloroquine Then Placebo for On-ART Participants8.00
D: Placebo Then Chloroquine for On-ART Participants7.00

Fasting Lipopolysaccharides (LPS) at Week 12

Results reported are the week 12 fasting LPS. (NCT00819390)
Timeframe: At week 12

Interventionpg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants14.37
B: Placebo Then Chloroquine for Off-ART Participants13.06
C: Chloroquine Then Placebo for On-ART Participants7.00
D: Placebo Then Chloroquine for On-ART Participants7.00

Fasting Lipopolysaccharides (LPS) at Week 24

Results reported are the week 24 fasting LPS. (NCT00819390)
Timeframe: At week 24

Interventionpg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants20.54
B: Placebo Then Chloroquine for Off-ART Participants2.83
C: Chloroquine Then Placebo for On-ART Participants7.00
D: Placebo Then Chloroquine for On-ART Participants8.00

HIV-1 RNA Copies/mL at Study Entry for Off-ART Participants

Results reported are for HIV-1 RNA (copies/mL) at study entry for off-ART participants. (NCT00819390)
Timeframe: At Entry

Interventionlog10 copies/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants4.48
B: Placebo Then Chloroquine for Off-ART Participants4.42

Number of Participants With Events Grade 3 or Higher

Events included signs and symptoms, laboratory abnormalities and/or clinical events grade 3 or higher which were described by site clinician blinded to the treatment arm as definitely or possibly related to the study treatment. (NCT00819390)
Timeframe: From start of study treatment to study completion at week 28

Interventionparticipants (Number)
A: Chloroquine Then Placebo for Off-ART Participants0
B: Placebo Then Chloroquine for Off-ART Participants1
C: Chloroquine Then Placebo for On-ART Participants1
D: Placebo Then Chloroquine for On-ART Participants0

Percent CD4 HLA-DR+/CD38+ at Baseline

Baseline CD4 HLA-DR+/CD38+ is computed as the mean of pre-entry and entry CD4 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At pre-entry and entry

Interventionpercent of CD4 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants8.5
B: Placebo Then Chloroquine for Off-ART Participants9.8
C: Chloroquine Then Placebo for On-ART Participants8.7
D: Placebo Then Chloroquine for On-ART Participants9.9

Percent CD4 HLA-DR+/CD38+ at Week 12

Results reported are the week 12 percentage of CD4 expressing HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Week 12

Interventionpercent of CD4 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants6.5
B: Placebo Then Chloroquine for Off-ART Participants10.5
C: Chloroquine Then Placebo for On-ART Participants7.7
D: Placebo Then Chloroquine for On-ART Participants9.0

Percent CD4 HLA-DR+/CD38+ at Week 24

Results reported are the week 24 percentage of CD4 expressing HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Week 24

Interventionpercent of CD4 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants11.0
B: Placebo Then Chloroquine for Off-ART Participants12.5
C: Chloroquine Then Placebo for On-ART Participants7.3
D: Placebo Then Chloroquine for On-ART Participants9.2

Percent CD8 CD38+ at Baseline

Baseline CD8 CD38+ is computed as the mean of pre-entry and entry CD8 CD38+. (NCT00819390)
Timeframe: At pre-entry and entry

Interventionpercent of CD8 expressing CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants71.0
B: Placebo Then Chloroquine for Off-ART Participants77.0
C: Chloroquine Then Placebo for On-ART Participants50.8
D: Placebo Then Chloroquine for On-ART Participants49.9

Percent CD8 CD38+ at Week 12

Results reported are the week 12 percentage of CD8 expressing CD38+. (NCT00819390)
Timeframe: At Week 12

Interventionpercent of CD8 expressing CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants71.5
B: Placebo Then Chloroquine for Off-ART Participants79.5
C: Chloroquine Then Placebo for On-ART Participants50.9
D: Placebo Then Chloroquine for On-ART Participants51.9

Percent CD8 CD38+ at Week 24

Results reported are the week 24 percentage of CD8 expressing CD38+. (NCT00819390)
Timeframe: At Week 24

Interventionpercent of CD8 expressing CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants78.0
B: Placebo Then Chloroquine for Off-ART Participants79.5
C: Chloroquine Then Placebo for On-ART Participants50.6
D: Placebo Then Chloroquine for On-ART Participants48.7

Soluble CD14 (sCD14) at Baseline

Baseline sCD14 was computed as the mean of pre-entry and entry sCD14. (NCT00819390)
Timeframe: At pre-entry and entry

Interventionmillion pg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants1.43
B: Placebo Then Chloroquine for Off-ART Participants1.97
C: Chloroquine Then Placebo for On-ART Participants1.80
D: Placebo Then Chloroquine for On-ART Participants1.58

Soluble CD14 (sCD14) at Week 12

Results reported are the week 12 sCD14. (NCT00819390)
Timeframe: At week 12

Interventionmillion pg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants1.53
B: Placebo Then Chloroquine for Off-ART Participants1.88
C: Chloroquine Then Placebo for On-ART Participants2.04
D: Placebo Then Chloroquine for On-ART Participants1.63

Soluble CD14 (sCD14) at Week 24

Results reported are the week 24 sCD14. (NCT00819390)
Timeframe: At week 24

Interventionmillion pg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants1.53
B: Placebo Then Chloroquine for Off-ART Participants2.19
C: Chloroquine Then Placebo for On-ART Participants1.77
D: Placebo Then Chloroquine for On-ART Participants1.72

HIV-1 RNA Copies/mL at Study Entry for On-ART Participants

Results reported are for HIV-1 RNA at study entry for on-ART participants. (NCT00819390)
Timeframe: At Entry

,
Interventionparticipants (Number)
at or below lower limit of quantitationabove lower limit of quantitation
C: Chloroquine Then Placebo for On-ART Participants162
D: Placebo Then Chloroquine for On-ART Participants172

HIV-1 RNA Copies/mL at Week 12 for On-ART Participants

Results reported are for HIV-1 RNA at week 12 for on-ART participants. (NCT00819390)
Timeframe: At week 12

,
Interventionparticipants (Number)
at or below lower limit of quantitationabove lower limit of quantitation
C: Chloroquine Then Placebo for On-ART Participants161
D: Placebo Then Chloroquine for On-ART Participants181

HIV-1 RNA Copies/mL at Week 24 for On-ART Participants

Results reported are for HIV-1 RNA at week 24 for on-ART participants. (NCT00819390)
Timeframe: At week 24

,
Interventionparticipants (Number)
at or below lower limit of quantitationabove lower limit of quantitation
C: Chloroquine Then Placebo for On-ART Participants142
D: Placebo Then Chloroquine for On-ART Participants181

HIV-1 RNA Copies/mL at Weeks 12 and 24 for Off-ART Participants

Results reported are for HIV-1 RNA (copies/mL) at week 12 and week 24 for off-ART participants. (NCT00819390)
Timeframe: At weeks 12 and 24

,
Interventionlog10 copies/mL (Median)
Week 12Week 24
A: Chloroquine Then Placebo for Off-ART Participants4.684.69
B: Placebo Then Chloroquine for Off-ART Participants4.284.61

IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Baseline

Baseline IL-6, sTNF-rI and D-dimer were computed as the mean of pre-entry and entry IL-6, sTNF-rI and D-dimer, respectively. (NCT00819390)
Timeframe: At pre-entry and entry

,,,
Interventionpg/mL (Median)
IL-6sTNF-rID-dimer
A: Chloroquine Then Placebo for Off-ART Participants1.651228.66286390
B: Placebo Then Chloroquine for Off-ART Participants1.621377.81328460
C: Chloroquine Then Placebo for On-ART Participants1.011316.63107890
D: Placebo Then Chloroquine for On-ART Participants1.511250.85103530

IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Week 12

Results reported are the week 12 IL-6, sTNF-rI and D-dimer. (NCT00819390)
Timeframe: At week 12

,,,
Interventionpg/mL (Median)
IL-6sTNF-rID-dimer
A: Chloroquine Then Placebo for Off-ART Participants1.681209.50251320
B: Placebo Then Chloroquine for Off-ART Participants1.281347.06319770
C: Chloroquine Then Placebo for On-ART Participants1.151441.35126540
D: Placebo Then Chloroquine for On-ART Participants1.301304.77117890

IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Week 24

Results reported are the week 24 IL-6, sTNF-rI and D-dimer. (NCT00819390)
Timeframe: At week 24

,,,
Interventionpg/mL (Median)
IL-6sTNF-rID-dimer
A: Chloroquine Then Placebo for Off-ART Participants1.341327.21264240
B: Placebo Then Chloroquine for Off-ART Participants1.181420.30294780
C: Chloroquine Then Placebo for On-ART Participants1.021230.21100860
D: Placebo Then Chloroquine for On-ART Participants1.271176.20124920

Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Baseline

Baseline percent activation levels of pDC were computed as the mean of pre-entry and entry percent activation levels of pDC. Similarly, baseline percent activation levels of mDC were computed as the mean of pre-entry and entry percent activation levels of mDC. (NCT00819390)
Timeframe: At pre-entry and entry

,,,
Interventionpercentage of cells (Median)
%pDC expressing CD80+%pDC expressing CD83+%pDC expressing CD86+%pDC expressing PDL-1+%mDC expressing CD80+%mDC expressing CD83+%mDC expressing CD86+%mDC expressing PDL-1+
A: Chloroquine Then Placebo for Off-ART Participants0.0345.489.122.521.0438.6096.299.82
B: Placebo Then Chloroquine for Off-ART Participants0.0336.159.356.130.8339.9497.5216.37
C: Chloroquine Then Placebo for On-ART Participants0.1319.9110.964.481.3148.1796.114.58
D: Placebo Then Chloroquine for On-ART Participants0.0723.6512.666.491.1726.0895.388.28

Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Week 12

Results reported are the week 12 percent activation levels of pDC and mDC. (NCT00819390)
Timeframe: At week 12

,,,
Interventionpercentage of cells (Median)
%pDC expressing CD80+%pDC expressing CD83+%pDC expressing CD86+%pDC expressing PDL-1+%mDC expressing CD80+%mDC expressing CD83+%mDC expressing CD86+%mDC expressing PDL-1+
A: Chloroquine Then Placebo for Off-ART Participants0.0051.907.663.740.8443.5197.9015.03
B: Placebo Then Chloroquine for Off-ART Participants0.0540.498.488.431.0336.4797.1816.32
C: Chloroquine Then Placebo for On-ART Participants0.1014.7013.937.241.4747.8395.407.10
D: Placebo Then Chloroquine for On-ART Participants0.1418.2013.645.161.0126.7595.156.09

Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Week 24

Results reported are the week 24 percent activation levels of pDC and mDC. (NCT00819390)
Timeframe: At week 24

,,,
Interventionpercentage of cells (Median)
%pDC expressing CD80+%pDC expressing CD83+%pDC expressing CD86+%pDC expressing PDL-1+%mDC expressing CD80+%mDC expressing CD83+%mDC expressing CD86+%mDC expressing PDL-1+
A: Chloroquine Then Placebo for Off-ART Participants0.0544.5010.134.340.9441.2197.709.53
B: Placebo Then Chloroquine for Off-ART Participants0.0038.967.897.451.1233.1997.0514.84
C: Chloroquine Then Placebo for On-ART Participants0.0814.8011.795.630.7636.6596.694.13
D: Placebo Then Chloroquine for On-ART Participants0.1617.6512.886.521.3924.1492.417.49

Reviews

2 reviews available for chloroquine and Acquired Immunodeficiency Syndrome

ArticleYear
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Effects of chloroquine on viral infections: an old drug against today's diseases?
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute

2003
Use of pyrimethamine-sulfadoxine (Fansidar) in prophylaxis against chloroquine-resistant Plasmodium falciparum and Pneumocystis carinii.
    Annals of internal medicine, 1987, Volume: 106, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria

1987

Other Studies

10 other studies available for chloroquine and Acquired Immunodeficiency Syndrome

ArticleYear
Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.
    Bioorganic & medicinal chemistry, 2012, Sep-01, Volume: 20, Issue:17

    Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Antimalarials; Dose-Response Relations

2012
Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science.
    Medical anthropology quarterly, 2020, Volume: 34, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Anthropology, Medical; Antimalarials; Antiviral Agents; Chloroqu

2020
Imported malaria in a non-endemic area: the experience of the university of Campinas hospital in the Brazilian Southeast.
    Malaria journal, 2014, Jul-22, Volume: 13

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anemia; Antimalarials; Artemether; Artemisini

2014
Hypothesis links emergence of chloroquine-resistant malaria and other intracellular pathogens and suggests a new strategy for treatment of diseases caused by intracellular parasites.
    Medical hypotheses, 2004, Volume: 62, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria

2004
The timing is right: Evolution of AIDS-causing HIV strains is consistent with history of chloroquine use.
    Medical hypotheses, 2006, Volume: 67, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Chloroquine; HIV; HIV Infections; Humans

2006
[Outbreak of malaria induced among users of injectable drugs].
    Revista de saude publica, 1993, Volume: 27, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Brazil; Child; Chloroquine; Cocaine; Disease

1993
Treatment of lymphoid interstitial pneumonia with chloroquine.
    The Journal of pediatrics, 1993, Volume: 122, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Child; Child, Preschool; Chloroquine; Female; HIV-2; Humans; Mal

1993
Malaria fighters gather at site of early victory.
    Science (New York, N.Y.), 1997, Sep-05, Volume: 277, Issue:5331

    Topics: Acquired Immunodeficiency Syndrome; Africa; Animals; Animals, Genetically Modified; Anopheles; Antim

1997
Treatment for AIDS and other retrovirus-caused diseases.
    Medical hypotheses, 1988, Volume: 27, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Animals; Chloroquine; Drug Therapy, Combination; Fluorouracil; H

1988
Lysosomotropic agents in AIDS treatment.
    The Western journal of medicine, 1987, Volume: 146, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Amantadine; Chloroquine; Humans

1987